文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-DOTATOC与177Lu-PSMA治疗对外周血淋巴细胞DNA损伤的差异

Dissimilar DNA Damage to Blood Lymphocytes After 177Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
PubMed 文献 · J Nucl Med · 2020-07-31

该研究采用γ-H2AX免疫荧光显微镜法,对比了48例接受177Lu-DOTATOC(26例)或177Lu-PSMA-617(22例)放射性配体治疗患者的外周血淋巴细胞辐射诱导焦点(RIF)。结果显示,尽管177Lu-PSMA组的血液剂量和剂量率在各时间点均显著更高,但177Lu-DOTATOC组在72小时后的RIF计数反而更高,提示现有血液剂量学模型存在局限。

要点

  • 注射后RIF计数在5分钟达峰,随后下降,PSMA组5分钟时显著高于DOTATOC组。
  • PSMA组血液剂量和剂量率在各时间点均显著高于DOTATOC组。
  • 72小时DOTATOC组RIF显著更高,且与血小板下降相关。

核心结论

  • 现有血液剂量学模型生成的数值与RIF计数相关,但无法解释177Lu-DOTATOC与177Lu-PSMA两组间的RIF差异。
  • 177Lu-DOTATOC组尽管剂量率和血液剂量更低,却观察到显著更多的RIF,暴露了潜在局限。

研究设计与样本

  • 研究纳入48例接受177Lu标记放射性配体治疗的患者,其中177Lu-DOTATOC组26例,177Lu-PSMA组22例。
  • 于基线及注射后5分钟、30分钟、4小时、24小时、48小时、72小时采集静脉血,用γ-H2AX免疫荧光显微镜量化淋巴细胞RIF。
  • 通过序贯血放射性浓度和γ相机成像推导血液吸收剂量与剂量率,并监测注射后3天血小板水平。

主要发现

  • 基线RIF计数平均为0.25 ± 0.15,注射后RIF计数显著高于基线,于5分钟达峰(平均3.93 ± 2.51)。
  • 177Lu-PSMA组RIF计数在注射后5分钟显著高于177Lu-DOTATOC组,而在72小时显著低于177Lu-DOTATOC组。
  • PSMA组血液剂量和剂量率在各时间点均显著高于DOTATOC组,但未能完全解释上述RIF差异。
  • RIF计数与所有时间点的剂量率相关(Pearson r = 0.78;P < 0.01),与吸收剂量仅在注射后4小时内相关(Pearson r = 0.42;P < 0.01)。
  • 血小板浓度下降与注射后72小时的RIF显著相关(Pearson r = -0.34;P < 0.05)。

临床怎么用

  • γ-H2AX RIF计数可作为评估放射性配体治疗所致淋巴细胞DNA双链断裂的生物学指标。
  • 解读血液剂量学结果时需注意其可能无法完全反映不同放射性配体间的生物学效应差异。

局限性

  • 原文未明确报告研究的局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA double-strand breaks in cells of radionuclide-treated patients are quantifiable by immunofluorescence microscopy, using phosphorylation of histone-variant H2AX (γ-H2AX) to mark radiation-induced foci (RIFs). Using this method, we compared excess RIFs side by side in recipients of 177Lu-DOTATOC or 177Lu-prostate specific membrane antigen-617 (PSMA) radioligands. We also examined relations between blood dose and dose rate, RIFs, and platelet counts. Methods: Venous blood samples were obtained from 48 patients subjected to 177Lu-labeled radioligand therapy (177Lu-DOTATOC, 26; 177Lu-PSMA, 22) to quantify blood lymphocyte RIFs and blood activity concentrations at various time points, including baseline (before injection) and postinjection readings (5 min, 30 min, 4 h, 24 h, 48 h, and 72 h). Absorbed doses and dose rates to blood were derived from sequentially assessed blood activity concentrations and γ-camera imaging. Platelet levels in routine blood tests were monitored for 3 d after injection to assess responses. Results: RIF counts averaged 0.25 ± 0.15 at baseline. Postinjection RIF counts were significantly higher than baseline values, peaking at 5 min (average, 3.93 ± 2.51 min) and declining thereafter. Compared with RIF counts of 177Lu-DOTATOC, those of 177Lu-PSMA were significantly higher at 5 min after injection and significantly lower at 72 h after injection. These differences could not be fully explained by blood doses and dose rates, which were significantly higher for 177Lu-PSMA than for 177Lu-DOTATOC treatment at every time point. RIF counts overall correlated with dose rates across all time points (Pearson r = 0.78; P < 0.01) and with absorbed dose until 4 h after injection only (Pearson r = 0.42; P < 0.01). Declines in platelet concentration correlated significantly with RIFs at 72 h after injection (Pearson r = -0.34; P < 0.05). Conclusion: Although values generated by the currently used blood dosimetry model correlated with RIF counts, the difference observed in 177Lu-DOTATOC and 177Lu-PSMA treatment groups was unexplained. Significantly more RIFs were found in 177Lu-DOTATOC recipients by comparison, despite lower dose rates and blood doses, exposing a potential limitation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ritt P, Jobic C, Beck M, et al. Dissimilar DNA Damage to Blood Lymphocytes After 177Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy. J Nucl Med. 2020. PMID: 32737244. doi:10.2967/jnumed.120.243782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。